Navigation Links
Hospira Expands Board of Directors With Election of Dennis M. Fenton
Date:7/31/2012

LAKE FOREST, Ill., July 31, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that Dennis M. Fenton, Ph.D., has been elected to the company's board of directors. Dr. Fenton, a recognized manufacturing and biologics expert, has more than 30 years of healthcare industry experience. The addition of Dr. Fenton expands Hospira's board to 11 directors, 10 of whom are independent. 

"We are excited to welcome Dennis to Hospira's board of directors," said John C. Staley, chairman of the board. "His impressive track record of results-oriented leadership and pioneering contributions to biological manufacturing and operations quality make him an excellent fit."

F. Michael Ball, chief executive officer, added, "Dennis brings unparalleled experience in the pharmaceutical and biotechnology space, with differentiated expertise that spans manufacturing and quality overall, and biologics in particular. His appointment supports Hospira's commitment to establish manufacturing as a competitive advantage."

Dr. Fenton, 60, spent more than two decades at Amgen, where he served as one of the company's longest-tenured employees and its executive vice president of Operations until his retirement in 2008. Prior to Amgen, Dr. Fenton served as a senior research scientist at Pfizer.

Dr. Fenton is a member of the Society for Industrial Microbiology, held previous memberships in the American Chemical Society, the American Society for Microbiology and the Parenteral Drug Association, and was a director of the Biotechnology Industry Organization (BIO) and National Health Foundation. He currently serves on the boards of Dendreon Corporation, Napo Pharmaceuticals, Genelux Corporation, Xenoport and Kythera Biopharmaceuticals; and is a trustee of the Keck Graduate Institute and Rutgers University. A native of New York, Dr. Fenton holds a Bachelor of Science degree in biology from Manhattan College and a doctorate in microbiology from Rutgers University.

About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
8. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
9. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
10. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
11. S1 Biopharma Expands Focus to Include Male Sexual Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 25, 2017 , ... Patients who would like to straighten ... fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria Chen, an ... this revolutionary treatment with or without a referral. , Wilckodontics is also ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving multi-billion ... head shops –can’t help but be heartened by the industry’s current surge. But another ... described as “skunk smell.” At last they can simply, safely and effectively end ...
(Date:4/25/2017)... ... ... There is no better place in South Florida to undergo two common heart ... of Consumer Reports focused on heart health. , The magazine gave Memorial ... bypass and aortic valve replacement procedures. , Consumer Reports rated Memorial’s Cardiac ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American ... pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in a ...
(Date:4/24/2017)... ... 2017 , ... As part of the nationwide Days of Remembrance effort led ... Holocaust and Nazi persecution, Center for Medicine after the Holocaust (CMATH) announced ... trip to Germany and Poland next week. , The Fourth Biennial CMATH Champions Trip ...
Breaking Medicine News(10 mins):